Compare BZH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BZH | AUPH |
|---|---|---|
| Founded | 1985 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 672.0M | 1.9B |
| IPO Year | 1995 | 2014 |
| Metric | BZH | AUPH |
|---|---|---|
| Price | $19.78 | $15.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $32.00 | $17.25 |
| AVG Volume (30 Days) | 329.2K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5075.00 |
| EPS | N/A | ★ 2.07 |
| Revenue | ★ $2,087,739,000.00 | $283,055,000.00 |
| Revenue This Year | $4.36 | $16.53 |
| Revenue Next Year | $10.79 | $16.24 |
| P/E Ratio | ★ N/A | $7.16 |
| Revenue Growth | N/A | ★ 20.38 |
| 52 Week Low | $17.37 | $6.83 |
| 52 Week High | $28.33 | $16.54 |
| Indicator | BZH | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 62.13 |
| Support Level | $18.93 | $14.56 |
| Resistance Level | $23.94 | $16.28 |
| Average True Range (ATR) | 0.71 | 0.53 |
| MACD | 0.04 | 0.11 |
| Stochastic Oscillator | 39.02 | 96.25 |
Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.